CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ: FMI) and EmergingMed today announced a partnership to offer personalized clinical trial navigation services to help health care providers and their patients who have received FoundationOne® or FoundationOne® Heme comprehensive genomic profiling. Through this concierge service, patients and their health care providers will receive assistance in identifying and accessing appropriate clinical trials. The clinical trial navigation service increases physicians’ ability to act on comprehensive genomic profiling results and more frequently consider clinical trial enrollment while making treatment decisions.
“The rapid progress in our understanding of the underlying genomic drivers of cancer has also driven accelerated development of targeted therapies, resulting in the hundreds of drug candidates currently under investigation in clinical trials,” said Vincent Miller, MD, chief medical officer, Foundation Medicine. “These investigational therapies offer relevant and rational options for patients with cancer, particularly for those whose cancer has progressed or returned following standard treatment. By providing clinical trial navigation services, we aim to facilitate timely and accurate clinical trial information and enrollment support services for physicians and patients, enabling greater access to treatment options based on the unique genomic profile of a patient’s cancer.”
Through this partnership, Foundation Medicine will make available EmergingMed’s highly skilled group of “Clinical Trial Navigators” to educate and match patients to clinical trials based on their specific genomic profiles and clinical characteristics. The Navigators refer patients and physicians to verified trial sites and offer assistance in navigating and overcoming addressable barriers in what can be a complex trial enrollment process. EmergingMed consistently reviews and curates a comprehensive database of clinical trials, structured eligibility criteria, and trial site contacts to maintain the most up-to-date, actionable referral solution. These services will be offered by Foundation Medicine to patients at no cost.
“Today cancer clinical trials offer patients access to over 800 targeted therapies in development, but timing is everything — patients and physicians must identify and act on relevant options when the patient’s clinical profile is aligned with the often short enrollment window for each trial,” said Courtney Hudson, CEO of EmergingMed. “By offering clinical trial navigation services, Foundation Medicine enhances each patient and physician’s ability to identify and act on clinical trial opportunities now and in the future. The service will also send updates to users when new clinical trials of targeted therapies emerge that match a patient’s specific genomic and clinical profile. We are pleased to offer these services and further expand treatment options for patients with cancer.”
The services are currently in the process of implementation and will be widely available to patients and their health care providers before the end of 2014. Inquiries about the service may be directed to Foundation Medicine’s client services at email@example.com and (888) 988-3639.
About Foundation Medicine
Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and pediatric cancers, provide a fully informative genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
FoundationOne is a fully informative genomic profile for solid tumors used by oncologists to identify the molecular alterations in a patient's tumor and match those alterations with relevant targeted therapies and clinical trials. Using next-generation sequencing in routine cancer specimens, FoundationOne interrogates all genes somatically altered in human cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. It reveals all classes of genomic alterations including base substitutions, insertions, deletions, copy number alterations and select rearrangements. FoundationOne fits easily into the clinical workflow of the ordering physician, and test results are provided in an easy-to-interpret report supported by a comprehensive review of published literature. FoundationOne is a laboratory-developed test performed at Foundation Medicine's CLIA-certified lab. Please visit www.FoundationOne.com for more information.
About FoundationOne® Heme
FoundationOne Heme is a fully informative genomic profile for hematologic cancers (leukemia, lymphoma and myeloma), as well as many sarcomas and pediatric cancers, designed to provide physicians with clinically actionable information to guide treatment options for patients based on the genomic profile of their cancer. It is Foundation Medicine's second commercially available targeted sequencing assay and was developed in collaboration with Memorial Sloan-Kettering Cancer Center. Using next-generation sequencing in routine cancer specimens, FoundationOne Heme interrogates all genes somatically altered in these cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. The test employs RNA sequencing in addition to DNA sequencing to simultaneously detect all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and rearrangements, and gene fusions (a type of alteration that is a common driver of hematologic malignancies. sarcomas and pediatric cancers). FoundationOne Heme fits easily into the clinical workflow of the ordering physician, and test results are provided in an easy-to-interpret report supported by a comprehensive review of published literature. FoundationOne Heme is a laboratory-developed test performed at Foundation Medicine's CLIA-certified lab. Please visit www.FoundationOne.com for more information.
Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.
EmergingMed® is the leading innovator in clinical trial enrollment optimization, providing solutions for managing the complexities of patient identification, recruitment and retention since 2000. We partner with trial sponsors, trial sites, research networks, patient advocates and molecular diagnostic companies. Our core solution is a turn-key, privately branded Clinical Trial Navigation Service (CTNS) featuring concierge support, patient education, and long term follow up; highly curated referral-quality data; multiple digital distribution channels; re-engineered business processes; and comprehensive service metrics and outcomes tracking. EmergingMed’s patented, patient-centric solution enables our partners to get the right information to the right person at the right time—and ensures the information is presented in context and readily actionable. Headquartered in Durham, NC with an office in New York, NY, EmergingMed’s CTNS has managed clinical trial searches for 200,000 cancer patients and 100,000 patients with other serious and life-threatening conditions. For more information, visit www.emergingmed.com or email ContactUs@emergingmed.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the benefits of Foundation Medicine’s partnership with EmergingMed, the ability of the clinical trial navigation services to identify and provide access to clinical trials and targeted therapies currently in development, and the ability of clinical trial navigation services to serve as a guide for the delivery of potentially appropriate treatment information. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that the clinical trial navigation services may not be able to identify relevant clinical trials with targeted therapies under development and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2013, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission, may be realized. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.